Buy Opdivo (Nivolumab)
Price range: €420.00 through €865.00
Select options
This product has multiple variants. The options may be chosen on the product page
Opdivo (nivolumab) is a drug used to treat certain types of cancer.
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with the following conditions:- metastatic melanoma as monotherapy or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after chemotherapy
- advanced renal cell carcinoma who have previously received anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) with disease progression during or within 6 months of receiving platinum-based chemotherapy
- locally advanced, unresectable or metastatic urothelial carcinoma after progression under platinum-based therapy
- Metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan
- hepatocellular carcinoma in patients previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ) with persistent pathological residual disease in patients who have received neoadjuvant radiochemotherapy (CRT).